We have recently reported the elimination in vivo of a syngeneic rat Moloney sarcoma (MST) 1 with an established blood supply, by remote intravenous infusion of syngeneic splenic effector cells with specificity for the tumor (1). The splenic effector cells were effective in vivo only after cytotoxicity of the population was augmented in an in vitro mixed lymphocyte tumor cell culture (MLTC). In this paper, we present data on the elimination of an established Moloney sarcoma with a blood supply, ranging from 1 to 7 cm in Diam, by infusion of varying numbers of specific effector cells. The specific effector cells were a subset of T blast cells, W3/25 + and W3/13 + (2), as detected by monoclonal antibodies to rat T antigens, and they apparently functioned as amplifier or helper cells in the tumor-bearing host. A W3/25-population, a melange of T cells, null cells, macrophages, and B cells, was associated with enhancement of tumor in vivo.
d MLTC with 150/~g of GARG in a volume of 0.5 ml of minimal essential medium or RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.), supplemented with 10% fetal bovine serum. The incubation period was 75 rain at 37°C, to strip SIg from the cell membrane of rat B ,'e~]~ and to prevent any cross-reactivity of GAMG for rat spleen cells. The cells, after incubation, were washed once in Hanks' balanced salt solution containing 2% bovine serum albumin (BSA) and 0.1% NAN3, resuspended in 50/~l of this medium, and then incubated for 30 rain at 4°C with 25 ~l of W3/13 at 1:10 dilution or W3/25 at 1:4 dilution. Cells were washed two times, resuspended in Hanks' balanced salt solution containing BSA and NaN.~, incubated with 20/.tg of FI-GAMG for 30 rain at 4°C, and washed three times before final suspension in medium. When T cells were fractionated in a fluorescence-activated cell sorter (FACS), W3/25 stained cells were kept in RPMI-1640 10% fetal bovine serum for the entire procedure.
SIg was detected with FI-GARG as described previously (6) . Ia was detected by incubating 3 × 106 spleen cells or cells ofa 7-d MLTC in 0.l ml with 25/~g of Fl-anti-Ia for 30 min at 4°C. Cells were washed three times, fixed by addition of 4% paraformaldehyde, final concentration 1%, washed once, and examined. Double labeling was carried out as follows: (a) for Ia and SIg, cells were first labeled with Rh-GARG to detect SIg, washed three times in Hanks balanced salt solution-10% rat serum and 0.1% NaN.~, and stained next with FI-anti-Ia; (b) for Ia and T antigens, cells were stained first with unlabeled W3/25 or W3/13 followed by Rh-GAMG to detect T antigens, washed three times in Hanks'-10% mouse serum and 0.1% NAN3, and next stained with Fl-anti-Ia. Fluorescence intensity and light scatter were determined in an FACS (FACS II; Div. FACS Systems, Beckton, Dickinson & Co., Oxnard, Calif.). The preamplifiers and laser beam were adjusted so that the fluorescence peak was at channel 280, and the scatter peak was at channel 230 when 5 ~m fluorescent beads were tested (Coulter Electronics Inc., Hialeah, Fla.). The coefficient of variation was about 10%. Cells in fluorescence channels 100-400 were classified as low density, and 400-1,000 as high density. Percentage of cells under each part of the fluorescence histogram was determined by the formula: number of cells in specified fluorescence channels/total number of fluorescent cells multiplied by 100. Positive W3/25 ceils were isolated by sorting in the FACS at 4-5,000/s. Cells in channels 0-90 were deflected left, and those in channels 110-1,000 were deflected right.
Depletion of B and T Lymphocytes. B cells were eliminated from effector populations by adherence to plastic Petri dishes coated with affinity purified F(ab')2 fragments of goat antibodies to rat immunoglobulins according to method of Mage et al. (8) . T cells were removed by lysis with an excess RART and guinea pig serum diluted 1:5 as a source of complement. RART plus complement treatment reduced day 7 immune T cells from 57 to 5%, as detected by W3/13.
Generation of Effector Cells. Rats were immunized by a subcutaneous injection with 10 e BM2 cells. Spleen cells were removed 7 wk later, 2 wk after the tumors had completely regressed. To augment cytotoxicity, immune spleen cells were cultured in vitro with MST-1 tumor cells treated with 50 pg/107 ceils/ml, of mitomycin C (Sigma Chemical Co., St. Louis, Mo.). Pretreatment of tumor cells with trypsin (0.5 g trypsin plus 0.2 g EDTA/liter for 5 min at 37°C in 95% air-5% CO2; trypsin EDTA (Flow Laboratories, Inc., Rockville, Md.) enhanced their immunogenicity as stimulating elements in the MLTC. The cultures were established in 75-cm 2 tissue culture flasks (Falcon Labware, Div. of Becton, Dickinson & Co.) at a ratio 5:1 spleen (E):tumor cells (T) and incubated for 7 d under the conditions previously described (1) . Cytotoxicity of spleen cells only from donor rats in which regression was complete could be augmented in vitro.
5tCr Release Assay. After 7 d of culture the cytotoxic spleen cell activity (CMC) was assessed in a 16-h siC-release assay as described previously (1). The 7-d cultures of immune spleen cells and mitomycin C-treated MST tumor cells (MSTMit) yielded the maximal CMC, ranging from 80 to 84% specific 51Cr release at E:T ratios of 50:1 to 100:1. In a microassay, 104 SlCr-labeled target cells were incubated at a ratio of50:1 with effector cells in 0.5-ml microtubes in a volume of 0.3 ml. In rats given cells from normal or progressor donor spleens that were cultured for 7 d in MLTC, growth of tumors was unaffected or enhanced. Fig. 1 reveals that despite infusion of large number of effector cells, a period of time was required (about 2 wk) before regression was recognizable. Furthermore, the larger the number of effector cells, the greater and sooner the effect on tumor growth. Similar results were also obtained in assay rats that were not irradiated except that tumor elimination was prolonged by several days (data not shown). Irradiated rats were reported in this paper because rate of growth of tumors in irradiated rats was less variable than in normal rats and because in a small proportion of normal hosts bearing a tumor, infusion of effector cells was inhibitory rather than curative (1) .
Challenge of Established Sarcomas In
In a second set of experiments, subcutaneous inocula of MST-1 were allowed to expand in size for 12 and 18 d after inoculation, when they were over 2.5 and 5.0 cm in Diam, respectively. These data are shown in Fig. 2 . The larger the tumor load at the time of infusion of effector cells, the greater the number of effector cells that was needed to eliminate the tumor. As before, there was c o n t i n u e d growth of t u m o r for 10-14 d after infusion of effector elements. E l i m i n a t i o n of a 12-d-old sarcoma required a m i n i m a l dose of 3 × l0 s effector cells, a n d complete elimination was achieved 50-60 d after injection. However, in 18-d-old sarcomas, the total n u m b e r of effector cells needed to induce detectable regression was 7.5 × l0 s, given in two intravascular infusions. T w o additiona! infusions of effector cells were administered even when it was apparent that MSF-1 was diminishing, in order to ensure that the t u m o r would not resume growth, Fig. 3 is a photograph showing the size of the t u m o r in one assay rat at its peak size on day 27 after inoculation of MST-1, a n d also its complete elimination by day 98. There was no recurrence in any of the rats cured of M S T sarcomas, some of them having been followed for more t h a n 18 mo. Furthermore, the treated rats retained the capability to reject a lethal dose of M S T -1 when challenged 1 yr later (data not shown). (Table I ). In the three groups of spleens at day 0, Ia ÷ T cells ranged from 1 to 3%. Our data II e value was calculated by Studem's t test and compares uulculttued (day 01 legu'ess<, spleen celN and day 7 MI.TC regressor spleen cells+ apparently underestimated the total number of Ia ÷ cells present on days 0 and 7. Fluorescence microscopy of day 0 spleen cells showed that about 30% are Ig ÷, and 90% of the Ig ÷ cells are Ia ÷. FACS analysis showed that 48% of cells are Ig ÷, hence, Ia-positive cells could be expected to be about 40%. Microscopic examination of 7-d cultures disclosed that 75% of the cells were blastlike cells (Fig. 4) : there were very few tumor cells and macrophages. With appropriate staining, of the blast cells 65% were T cells; there were also about 10% Ig ÷ cells. In 7-d cultures of progressor and normal spleens, there were relatively large numbers of tumor cells, few blast cells, and some large vacuolated elements, which may have been macrophages (Fig. 4) . A light scatter histogram disclosing the change in cell size of 7-d MLTC cultures of regressor spleens confirmed a significant shift from small to large cells. Over 70% of day 7 cultures were larger than average spleen cells of day 0 cultures (data not shown).
The observations recorded in Table I and Fig. 4 implicated T cells as the main effector ceil'population. T cells were, therefore, reacted with W3/13 and W3/25 anti-T reagents and examined in a FACS for staining intensity, i.e., for density of T antigens on T cell surfaces. Cultures, prepared immediately after removal of spleens from donor rats and from cultures of 7-d MLTC, were labeled. Results are shown in Fig. 5 and Table II. In Table II cells were analyzed for their fluorescence intensity: low intensity channels 100-400, and high intensity, channels 400-1,000. The significant change in the day 7 effector cell population was an increase of poorly stained T cells and a significant decrease of brightly stained cells when F~-W3/13 was used. This decrease in fluorescence intensity occurred on cells that had increased in size as determined by light scatter. The opposite changes occurred when FI-W3/25 was used (Fig. 5) . With infusion of W3/25 + T subset, an inoculum of 105 MST given subcutaneously 6 d before was completely eliminated in 6-8 d. W3/25-cells were ineffective against the established tumor; indeed, MST was significantly larger than tumors in control rats. 10-15 × 106 unfractionated day 7 immune spleen cells inhibited, but did not eliminate, the tumor. This type of experiment has been performed four times with similar results. However, when the sorted W3/25 + T lymphocytes could not be infused in sufficient numbers into rats bearing a 0.7-to l-era sarcoma, growth of the tumor was inhibited, but MST was not eliminated; the challenged hosts survived 75-95 d. In assay rats treated with W3/25-cells, tumors were larger than in controls, and challenged hosts survived 28-30 d. Mean survival time in untreated controls was 38 ±4dSE.
Elimination of Tumor In
A number of other fractionated populations of effector cells were assayed as described above. 10-50 × 106 immune spleen cells deprived of T cells by lysis with (7) <0.01 400-1,000 7 ± 1 (4) 5 ± 1 (4) 28 ± 4 (7) <0.0l RART and complement (C) were ineffective against MST (Fig. 6) . At an E:T ratio in vivo of 1,000:1 (1 × 108 immune spleen cells), the tumor was inhibited but not populations. A (W3/13 +, W3/25-) T cell population could not be obtained in sufficient numbers to infuse into tumor-bearing rats.
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In Vitro Cytotoxicity of Fractionated T Effector Cells. Immune spleen cells of 7-d cultures in MLTC were sorted in a FACS into W3/25 + and W3/25-populations. These and the unfraetionated cultures containing W3/25 + and W3/25-populations were tested for cytotoxicity against target MST-1 in 51Cr release assays. Fig. 7 gives the results of these experiments and represents the mean of three trials, each trial carried out in triplicate; the standard error of the mean did not exceed 10% for these experiments. W3/25 + cells were poorly cytotoxic; cytotoxicity ranged from 11 to 13% specific 51Cr release. W3/25-cells were more effective, displaying 22-50% specific 51Cr release. The unfractionated mixed population from which W3/25 + and W3/25-were derived, under similar experimental conditions, yielded specific ~ZCr release of 37-62% at ratios of 20:1 to 50:1. Also, removal of T lymphocytes by treatment with RART and C decreased in vitro cytotoxicity to cytotoxic against MST (average 70% 51Cr release Cytotoxicity of unfractionated immune spleen mycin C-treated MST (MSTMit) was augmented less than 10%. W3/13 + cells were at an E:T of 50:1). cells, incubated for 7 d with mitoto 60-70% 51Cr release; at the time of removal from donor rats, immune spleen cells showed a 10% 51Cr release against MST (1). Control spleen cells, immune spleen ceils cultured without antigenic stimulation, and immune spleen cells cultured with an unrelated tumor (BC5), showed no augmentation of~Cr release after 7 d in culture, and were ineffective in vitro and in vivo against MST (1). These results indicate that in vitro culture with the specific tumor antigens is necessary to augment effector function of infused cells.
Discussion
There has been a plethora of reports describing either protection, prevention, or elimination in vivo of syngeneic or allogeneic tumor by injection of cytotoxic effector However, a number of papers described the elimination of tumors after they have been inoculated into test animals, usually 3-5 d before administration of effector cells (14, 15, 17, 19, 20, 23-26, 28, 31, 46, 56, 57, 62, 70, 73) when the tumors ranged from 0.5 to 2.0 cm in Diam. In some models combined immuno-and chemotherapy have been applied (19, 22, 24-26, 30, 31, 48, 50, 51, 59, 62, 63) .
In our model, established sarcomas of large size (1-7 cm) and relatively long duration (18 d) were completely and permanently eliminated, by remote infusion of syngeneic effector T lymphocytes that were stimulated a second time by the specific antigen, i.e., by MST-1 tumor. Several rough calculations reveal that a 5-cm in Diam 5-g tumor is about 3% of the body weight (165 g) of the test rats bearing the tumors. If translation to human proportions is permissible, this represents a 2-kg neoplasm in a 70-kg adult. In addition, tumors were expanding for 18 d before treatment was started; jn 100-d-old test rats, this is 18% of their lives, or in human terms, about 3.5 yr of a 20-yr-old adult. Regression of these large tumors (5-6 g), which we estimate to contain not less than 5 x l0 a viable tumor cells, was visible after infusion of 7.5 x l08 effector cells, which is about two times the number of cells that can be recovered from an adult BN spleen. The W3/25 ÷ effector population was about 4 × 108 cells.
The subset associated with elimination of established tumors was defined by W3/ 25 +, W3/13 ÷ blast cells. However, in vitro this subset was poorly cytotoxic for MST-1. These disparate results suggested that the (W3/25 ÷, W3/13 ÷) T cell functioned as a helper or amplifier cell in the tumor-bearing host and that elimination of MST-1 required participation by the host. In support of this was the following observation. There was a time lag between infusion of effector cells and noticeable regression of tumor. If W3/25 ÷, W3/13 + cells were directly cytotoxic in vivo, one might have expected an immediate or almost immediate effect on tumor size. Instead, there was continued tumor expansion for 10-14 d after effector cell infusion. In addition, White et al. (74) have provided some evidence that the W3/25 ÷ cell functions as a helper cell. However, we cannot exclude the possibility that the W3/25 ÷ cell may be converted to a cytotoxic effector cell after transfer to the assay animal, or that a small number of cytotoxic cells contained in the effector cell population expand to kill the tumor.
The biological significance of the surface membrane markers on the cells of the effector subset is still undefined. In the MLTC, a T cell subset was expanded in response to tumor antigens and transformed into blast elements. With these changes there was an increase in the W3/25 antigen on the cell surface and a decrease of W3/ 13 antigen. We have not determined whether the W3/25 + antigen is obligatory for helper function and whether its presence determines function or vice versa. Ia antigens, at least the ones detected by the antiserum used, seem not to be related to the in vitro function of W3/25 ÷ cells. In preliminary experiments when immune spleen cells of 7-d cultures were depleted of Ia-positive cells by anti-Ia antibody plus C or when Ia antigens were stripped from the lymphocyte membrane by capping, in vitro cytotoxicity was the same as that observed with populations that were Ia +. Several recent reports have emphasized that Ia antigens of the I-A region of major histocompatibility complex are associated with amplifier T cells (75, 76) ; other reports indicate that Ia antigens, particularly those related to the I-J region, are associated with cytotoxic T cells (77) (78) (79) . Ia antigens may merely be a differentiation marker or a marker for cell activation (75, (80) (81) (82) (83) . In our model, the acquisition of Ia during MLTC appears to have a positive relationship with cell activation because cell cultures from normal spleens, from spleens derived from rats with progressive tumors, and from regressor donor spleens that failed to become cytotoxic and to eliminate tumors in vivo, contained only 3-5% Ia + T cells and also very few T-blast forms. The W3/25-population was associated with enhancement of MST-1 in vivo and with moderate cytotoxicity for MST-1 in vitro. The W3/25-population was a melange of cells that included (W3/13 +, W3/25-) T cells (about 14% of this population), null cells, Ig + cells, and 1-3% macrophages. Suppressor cells were likely contained in the W3/25-population, as is suggested by the tumor enhancement in vivo and by the failure of small numbers of unfractionated cells (containing a mixture of 5-7 X 10 n W3/25 ÷ and 5-7 × 10 n W3/25-) to eliminate tumor as shown in Fig. 6 . However, this possible inhibitory effect would be overcome when higher numbers of unfractionated cells are used (Fig. 1) . The phenotype of the suppressor element has not been identified. Suppressor T cells have been shown to operate in a model in vivo with established tumors (73) . We also have not ascertained the cytotoxic cell contained in W3/25-population. The in vitro cytotoxicity results suggest that one of the cytotoxic cells is a W3/13 + T cell. A null cell with antibody to viral antigens might also be operative (E. Fernandez-Cruz and J. D. Feldman. Unpublished observations.).
Our observations in this in vivo tumor model suggest that successful elimination of an expanding tumor depends upon a balance of helper cell activity overriding suppressor cell activity with participation of the host to provide the cytotoxic elements. If there are insufficient helper cells or too many suppressor elements, there will be no participation by the host and no provision of cytotoxic cells. The manipulations and use of immune effector cells in this rat model are applicable to human neoplastic conditions. With methods available to grow T cell lines with specific reactivities (81, (84) (85) (86) (87) , it is conceivable that a T lymphocyte subset could be isolated from peripheral blood or draining lymph nodes of humans bearing tumors and could be cultivated in vitro into permanent cell lines. These T cell lines, selected by their specific anti-tumor reactivities, could be returned to the tumorous patient in any number of effector cells needed.
Summary
Established subcutaneous Moloney sarcomas (MST-1) of large size and long duration were eliminated from syngeneic rats by intravenous infusion of varying numbers of specific syngeneic effector T lymphocytes. Spleen cells from BN rats in which tumor had regressed were cultured in an in vitro mixed lymphocyte tumor cell culture (MLTC) to augment cytotoxieity of effector cells. In the MLTC: a T cell subset was expanded in response to MST-1 antigens and transformed into blast elements. With these changes, there was an increase in the W3/25 antigen on the T cell surface, a decrease of W3/13 antigen, and an increase in the number of T cells with Ia antigens. The subset associated with elimination of established tumors was a blast T celt W3/25 ÷, W3/13 +, as detected by monoclonal antibodies to rat T antigens. The W3/25 + subset was poorly cytotoxic in vitro for MST-1 and apparently functioned in vivo as an amplifier or helper cell in the tumor-bearing host. The W3/25-population was a melange of cells that included (W3/13 +, W3/25-) T cells, null cells, Ig + cells, and macrophages, and was associated with enhancement of tumor in vivo, suggesting the presence of suppressor cells.
